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Human exposure to some industrial com-
pounds may result in adverse health outcomes
mediated through the neuroendocrine axis.
These chemicals may affect the synthesis, secre-
tion, transport, binding, action, or elimination
of natural hormones in the human body that
are responsible for maintaining homeostasis,
reproduction, development, and/or behavior
[U.S. Environmental Protection Agency (EPA)
1997]. In addition to being essential for nor-
mal brain development, thyroid hormones
play an important role in many physiologic
systems, and alterations in thyroid hormone
levels can lead to a myriad of adverse clinical
conditions (Nussey and Whitehead 2001).
Although much is still unknown about mecha-
nisms and consequences involved with the
relationship between environmental exposures
and changes in thyroid hormone levels, phtha-
lates and other environmental chemicals may
bind to thyroid receptors and inﬂuence thyroid
hormone signaling (Zoeller 2005). 
Phthalates are used extensively in many
personal-care and consumer products, result-
ing in widespread nonoccupational human
exposure through multiple routes and media
(Hauser and Calafat 2005). High-molecular-
weight phthalates [e.g., di(2-ethylhexyl)
phthalate (DEHP)], are primarily used as plas-
ticizers in the manufacture of flexible vinyl,
which is then used in consumer products,
flooring and wall coverings, food contact
applications, and medical devices [Agency for
Toxic Substances and Disease Registry
(ATSDR) 2002; Hauser and Calafat 2005].
Low-molecular-weight phthalates [e.g., diethyl
phthalate (DEP), dibutyl phthalate (DBP)]
are used in personal-care products (e.g., per-
fumes, lotions, cosmetics), as solvents and
plasticizers for cellulose acetate, and in formu-
lating lacquers, varnishes, and coatings,
including those used to provide timed releases
in some pharmaceuticals (ATSDR 2001;
Hauser and Calafat 2005). The Centers for
Disease Control and Prevention’s (CDC)
Third National Report on Human Exposure to
Environmental Chemicals (CDC 2005)
showed that the majority of males in the
United States have detectable concentrations
of several phthalate monoesters in urine
[monoethyl phthalate (MEP), mono(2-ethyl-
hexyl) phthalate (MEHP), monobutyl phtha-
late (MBP), and monobenzyl phthalate
(MBzP)], reﬂecting widespread exposure to the
parent diester compounds among the general
population. Two oxidative metabolites of
DEHP, mono-(2-ethyl-5-hydroxylhexyl)
phthalate (MEHHP) and mono-(2-ethyl-5-
oxohexyl) phthalate (MEOHP), were present
in most subjects at urinary concentrations
higher than those of MEHP, the hydrolytic
metabolite of DEHP (CDC 2005). 
Animal studies have shown that some
phthalates, namely DBP, butylbenzyl phtha-
late (BBzP), and DEHP, cause testicular toxic-
ity and other adverse male reproductive health
outcomes (ATSDR 2001, 2002; Hauser and
Calafat 2005), whereas human studies on
phthalate exposure and male reproductive
health have been inconsistent (Duty et al.
2003a, 2003b; Hauser et al. 2006; Hauser and
Calafat 2005; Jonsson et al. 2005; Murature
et al. 1987; Rozatti et al. 2002). Studies inves-
tigating the association between exposure to
phthalates and thyroid function are limited. In
animal studies, rats with diets contaminated
with DEHP were found to have thyroid altera-
tions and lower plasma thyroxine (T4) concen-
trations compared with controls (Hinton et al.
1986; Howarth et al. 2001; Poon et al. 1997;
Price et al. 1988). In addition, a recent in vitro
study reported that DEHP and other phtha-
lates caused changes in the iodide uptake of
thyroid follicular cells (Wenzel et al. 2005). A
dose-dependent inverse association between
DBP and both triiodothyronine (T3) and T4
has also been reported in male rats (O’Connor
et al. 2002). We are unaware of human studies
on phthalates and thyroid function; therefore,
we designed the present study to investigate
potential relations between biological markers
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BACKGROUND: Phthalates are used extensively in many personal-care and consumer products,
resulting in widespread nonoccupational human exposure through multiple routes and media. A
limited number of animal studies suggest that exposure to phthalates may be associated with altered
thyroid function, but human data are lacking. 
METHODS: Concurrent samples of urine and blood were collected from 408 men. We measured
urinary concentrations of mono(2-ethylhexyl) phthalate (MEHP), the hydrolytic metabolite of
di(2-ethylhexyl) phthalate (DEHP), and other phthalate monoester metabolites, along with serum
levels of free thyroxine (T4), total triiodothyronine (T3), and thyroid-stimulating hormone (TSH).
Oxidative metabolites of DEHP were measured in urine from only 208 of the men. 
RESULTS: We found an inverse association between MEHP urinary concentrations and free T4 and
T3 serum levels, although the relationships did not appear to be linear when MEHP concentrations
were categorized by quintiles. There was evidence of a plateau at the fourth quintile, which was
associated with a 0.11 ng/dL decrease in free T4 [95% conﬁdence interval (CI), –0.18 to –0.03] and
a 0.05 ng/mL decrease in T3 (95% CI, –0.10 to 0.01) compared with the first (lowest) MEHP
quintile. The inverse relationship between MEHP and free T4 remained when we adjusted for
oxidative metabolite concentrations; this simultaneously demonstrated a suggestive positive associa-
tion with free T4.
CONCLUSIONS: Urinary MEHP concentrations may be associated with altered free T4 and/or total
T3 levels in adult men, but additional study is needed to confirm the observed findings. Future
studies must also consider oxidative DEHP metabolites relative to MEHP as a potential marker of
metabolic susceptibility to DEHP exposure. 
KEY WORDS: biomarkers, endocrine disruption, epidemiology, hormone, phthalates, thyroid, urinary
metabolites. Environ Health Perspect 115:1029–1034 (2007). doi:10.1289/ehp.9852 available via
http://dx.doi.org/ [Online 12 March 2007]of phthalate exposure and levels of T4, T3, and
thyroid-stimulating hormone (thyrotrophin,
TSH) in adult men. 
Methods
Subjects were recruited from an ongoing study
on the relationship between environmental
agents and male reproductive health. They
were men who were partners in subfertile cou-
ples seeking evaluation between January 2000
and May 2004 from the Vincent Burnham
Fertility Center at Massachusetts General
Hospital (Boston, MA). The study was
approved by the Human Studies Institutional
Review Boards of the Massachusetts General
Hospital, Harvard School of Public Health,
the CDC, and the University of Michigan.
After the study procedures were explained and
all questions answered, subjects signed an
informed consent. Men 18–55 years of age,
who were not postvasectomy, were eligible to
participate. Of those approached, approxi-
mately 65% consented. Most men who
declined to participate in the study cited lack
of time on the day of their clinic visit as the
reason for not participating. 
Phthalate metabolites in urine. On the day
of each subject’s clinic visit, a single spot urine
sample was collected into a sterile specimen
cup prescreened for phthalates. Phthalate
metabolites were measured in urine because of
potential sample contamination from the par-
ent diester and because the metabolites, as
opposed to the parent diesters, are believed to
be the active toxicants (Li et al. 1998; Peck and
Albro 1982). The analytical approach for the
analysis of the urinary phthalate monoester
metabolites (i.e., MEHP, MBP, MBzP, and
MEP) and two oxidative metabolites of DEHP
(i.e., MEHHP and MEOHP) involved enzy-
matic deconjugation of the metabolites from
their glucuronidated form, solid-phase extrac-
tion, separation with HPLC, and detection by
isotope-dilution tandem mass spectrometry
(Blount et al. 2000; Silva et al. 2003, 2004b).
Detection limits were in the low nanogram
per milliliter range and varied slightly by ana-
lytical batch for each phthalate metabolite
(MEP, 1.00–1.21 ng/mL; MBP, 0.60–1.07
ng/mL; MBzP, 0.47–1.0 ng/mL; MEHP,
0.87–1.20 ng/mL; MEHHP, 0.95–1.60
ng/mL; MEOHP, 1.07–1.20 ng/mL). We
used isotopically labeled internal standards and
conjugated internal standards to increase preci-
sion of measurements. Along with the
unknown samples, each analytical run included
calibration standards, reagent blanks, and qual-
ity control materials of high and low concen-
trations to monitor for accuracy and precision.
Analysts at the CDC were blind to all informa-
tion concerning subjects. Urinary phthalate
metabolite concentrations were adjusted for
urine dilution by specific gravity (SG) using
the following formula: 
Pc = P[(1.024 – 1)/(SG – 1)], 
where Pc is the SG-adjusted phthalate metabo-
lite concentration (nanograms per milliliter),
P is the observed phthalate metabolite concen-
tration, and SG is the specific gravity of the
urine sample. SG was measured using a hand-
held refractometer (National Instrument
Company, Inc., Baltimore, MD).
Using the urinary concentrations of the
three DEHP metabolites (i.e., MEHP,
MEHHP, and MEOHP), we calculated the
percentage of these DEHP metabolites excreted
as the hydrolytic monoester (MEHP%). We
consider the MEHP% a phenotypic marker
of the proportion of DEHP metabolized to
and excreted in the urine as MEHP. The
greater the MEHP%, the larger the percent-
age of DEHP excreted as MEHP relative to
the excretion of the two oxidative metabolites.
To calculate MEHP%, we converted MEHP,
MEHHP, and MEOHP concentrations to
nanomoles per milliliter; divided MEHP con-
centrations by the sum of concentrations of
MEOHP, MEHHP, and MEHP; and multi-
plied by 100. To our knowledge, the use of
MEHP% as a phenotypic marker of DEHP
metabolism and excretion is novel and has
not been used in human health studies until
recently (Hauser et al. 2006).
Thyroid hormones and TSH. One non-
fasting blood sample was drawn between
0900 and 1600 hours on the same day the
urine sample was collected. Blood samples
were centrifuged and serum stored at –80°C
until analysis. Free T4, total T3, and TSH
concentrations were determined in serum by
microparticle enzyme immunoassay using an
automated immunoassay system (AxSYM;
Abbott Diagnostics, Abbott Park, IL). The
assay sensitivities for free T4 and total T3 were
0.01 ng/dL and 0.15 ng/mL, respectively.
The interassay coefﬁcients of variation (CVs)
for both hormones were < 9%. For TSH, the
ultrasensitive hTSH II assay was used with a
functional sensitivity of 0.03 µIU/L and
interassay CVs of < 8%.
Statistical analysis. Data analysis was per-
formed using SAS version 9.1 (SAS Institute
Inc., Cary, NC). Descriptive statistics on sub-
ject demographics were tabulated, along with
the distributions of phthalate metabolite con-
centrations and thyroid hormones. For phtha-
late metabolite values below the limit of
detection (LOD), an imputed value equal to
one-half the LOD was used. Thyroid hormone
and phthalate metabolite concentrations were
stratiﬁed by demographic categories to investi-
gate the potential for confounding. We used
multivariate linear regression to explore
relationships between thyroid hormones and
urinary phthalate metabolite concentrations.
Concentrations of T4 and T3 closely approxi-
mated normality and were used in statistical
models untransformed; the distribution of
TSH concentration was skewed left and was
therefore log-transformed for statistical analy-
ses. SG-adjusted phthtalate metabolite concen-
trations were also log-transformed. Inclusion of
covariates was based on statistical and biologic
considerations (Kleinbaum et al. 1998). Age
and body mass index (BMI) were modeled as a
continuous variable; smoking status was
dichotomized by current smoker versus never
smoked or former smoker; and race was cate-
gorized into four groups: white, African
American, Hispanic, and other. We considered
previous examination for infertility (yes or no),
prior impregnation of a partner (yes or no),
and timing of blood/urine samples by season
(winter vs. spring, summer, or fall) and time of
day (0900–1259 hours vs. 1300–1600 hours)
for inclusion in the models as dichotomous
variables. To improve interpretability, the
regression coefﬁcients were back transformed
and expressed as a change in the dependent
variable (i.e., hormone levels) for an interquar-
tile range (IQR) increase in phthalate metabo-
lite concentrations. For MEHP, we also
included MEHHP or MEHP% in the models,
in addition to an interaction term, to explore
evidence of whether individual differences in
DEHP metabolism alter susceptibility to
MEHP. Because, as expected, MEHHP and
MEOHP are highly correlated (r = 0.98), the
results for models including MEHHP were
identical to those with MEOHP and are there-
fore not presented. Our hypothesis is that the
concentrations of MEHHP (or MEOHP)
and/or MEHP% may represent phenotypic
markers for efﬁcient or inefﬁcient metabolism
of DEHP to its oxidative metabolites. In sec-
ondary analyses, the multivariate models were
rerun after excluding men with highly concen-
trated or highly dilute urine samples (SG
> 1.03 or < 1.01) (Teass et al. 1998). Finally,
we also assessed nonlinear relationships
between phthalate metabolite concentrations
and hormones by regressing the hormones on
quintiles of phthalate metabolites. 
Results
Of the 478 men with phthalate metabolites
measured in urine, 422 had free T4, total T3,
and TSH levels measured in serum. An addi-
tional 14 subjects taking hormone medications
(e.g., propecia, ﬁnasteride, cabergoline, clomid,
gonadotropin-releasing hormone, testosterone,
prednisone taper) were excluded from the pre-
sent analysis. In addition, none of the men
reported taking medications that may alter the
thyroid axis (i.e., amidoarone, carbamazepine,
chlorpropamide, carbidopa/levodopa, heparin,
interferon, lithium, phenytoin, phenobarbital,
propylthiouracil, sulfasalazine, synthroid).
Among the remaining 408 subjects (Table 1),
most were white (85%) and had never smoked
(72%). The mean (± SD) age and BMI were
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Distributions of SG-adjusted phthalate
metabolite concentrations are presented in
Table 2, and distributions of the thyroid hor-
mones and TSH measured in serum are pre-
sented in Table 3. Among the 408 urine
samples, MEP, a metabolite of diethyl phtha-
late, was detected in 100% of the samples,
whereas MBP and MBzP were detected in
> 97% and > 94% of the samples, respectively.
Of the samples, 83% had detectable concen-
trations of MEHP. The sample size for
MEOHP and MEHHP was 208 because ana-
lytical methods for the quantiﬁcation of these
analytes were only recently implemented in
this study. More than 95% of these samples
had detectable concentrations of MEHHP
and MEOHP. Spearman correlations between
MEHP and MEHHP or MEOHP were 0.74
and 0.71, respectively. 
Age was inversely associated with both free
T4 and total T3 (Spearman correlation coefﬁ-
cients were –0.2 and –0.1, respectively;
p < 0.05 for both), whereas there were sugges-
tive positive weak associations of BMI with
T3, TSH, MBzP, and both oxidative DEHP
metabolites (all Spearman correlation coeffi-
cients were 0.1; all p-values were between 0.05
and 0.1). Current smokers had higher median
T3 levels (1.04 ng/mL) and lower median
TSH (1.1 µIU/mL) than never-smokers
(0.96 ng/mL and 1.5 µIU/mL, respectively).
Smoking status was not associated with T4.
Samples collected in winter had median T4
concentrations slightly lower than those col-
lected in spring, summer, or fall (1.1 vs.
1.2 ng/dL), and median TSH was higher in
samples collected in the morning compared
with samples collected in the afternoon (1.5
vs. 1.4 µIU/mL). For the SG-adjusted phtha-
late metabolites, current smokers had higher
median concentrations of MEP (215 ng/mL)
but lower concentrations of MEHHP and
MEOHP (21 ng/mL and 16 ng/mL, respec-
tively) compared with never-smokers (140, 45,
and 32 ng/mL respectively). As previously
observed (Silva et al. 2004a), median MEHP
concentrations were also higher among men
whose urine samples were collected in the
afternoon (9.4 ng/mL) compared with men
who provided urine samples in the morning
(6.9 ng/mL).
Crude regression results were similar to
the adjusted results, with the exception of
MEP, where there was a suggestive inverse
association with total T3 (p = 0.07) and a sug-
gestive positive association with TSH (p = 0.1)
that were no longer evident when covariates
were included in the models (p = 0.2). Results
from the multivariate regression analyses are
presented in Table 4. All models were adjusted
for age, BMI, smoking, and the time of day
blood/urine samples were collected. We found
an inverse association between SG-adjusted
urinary MEHP concentration and serum total
T3 levels, where an IQR increase in MEHP
was associated with a 0.021-ng/mL decrease in
T3 [95% conﬁdence interval (CI), –0.042 to
–0.001 ng/mL; p = 0.04]. For the median
level of T3 (0.96 ng/mL), this represents a
2.2% decrease in T3 for an IQR increase in
MEHP (3.16–21.3 ng/mL). In sensitivity
analyses, effect estimates from the multivariate
models were similar when men with SG out-
side the acceptable range were excluded
(n = 339; results not shown).
When the analysis was limited to the sub-
set of men with oxidative DEHP metabolite
measures (n = 208), the inverse association
between MEHP and T3 became weaker. An
IQR increase in MEHP was associated with a
0.011-ng/mL decrease in T3 (95% CI,
–0.021 to 0.009 ng/mL; p = 0.4). However,
there was an inverse association between
MEHP% and free T4 (Table 4). An IQR
increase in MEHP% was associated with a
0.030-ng/dL decrease in free T4 (95% CI
–0.055 to –0.005 ng/dL; p = 0.02). For the
median T4 level (1.2 ng/dL), this represents a
2.5% decrease in T4 for an IQR increase in
MEHP% (6% to 17% MEHP). When both
Phthalates and thyroid hormones
Environmental Health Perspectives • VOLUME 115 | NUMBER 7 | July 2007 1031
Table 1. Subject demographics (n = 408).
Characteristic Mean ± SD No. (%)
Age (years) 36.2 ± 5.34
BMIa 27.8 ± 4.52
Race
White 346 (85)
Black/African American 15 (4)
Hispanic 19 (5)
Other 28 (7)
Smokingb
Never-smoker 292 (72)
Ever-smoker 113 (28)
Current smoker 38 (9)
Former smoker 75 (18)
Season of blood sample
Winter 111 (27)
Spring, summer, fall 297 (73)
Time of blood sample
0900–1259 hours 171 (42)
1300–1600 hours 237 (58)
aInformation on BMI missing for 2 subjects. bInformation
on smoking status missing for 3 subjects.
Table 2. Distribution of SG-adjusted phthalate metabolites in urine (ng/mL).
Phthalate Percentiles
metabolite No. GM 10th 25th 50th 75th 90th 95th Max
MEP 408 184 29.8 59.9 158 535 1,391 2,343 11,371
MBP 408 16.7 5.01 10.4 17.0 30.4 45.6 65.1 14,459
MBzP 408 7.70 2.40 4.20 8.16 15.7 24.9 42.4 520
MEHP 408 8.28 0.96 3.16 7.95 21.3 66.7 127 876
MEHHP 208 58.2 13.4 23.4 48.9 113 332 786 4,805
MEOHP 208 38.5 8.80 16.3 32.9 71.3 228 497 3,063
MEHP% 208 9 3 6 10 17 25 31 61
Abbreviations: GM, geometric mean; max, maximum.
Table 3. Distribution of thyroid hormones and TSH in serum (n = 408).
Percentiles
Hormone Meana 5th 10th 25th 50th 75th 90th 95th
Free T4 (ng/dL) 1.25 0.94 0.99 1.08 1.20 1.40 1.56 1.72
Total T3 (ng/mL) 0.97 0.70 0.76 0.83 0.96 1.08 1.21 1.25
TSH (µIU/mL) 1.43 0.62 0.77 1.04 1.43 1.95 2.77 3.58
aArithmetic mean presented for free T4 and total T3, and geometric mean presented for TSH.
Table 4. Adjusteda regression coefﬁcients (95% CI) for thyroid hormones associated with an interquartile
range (IQR) increase in SG-adjusted urinary phthalate metabolite concentrations (n = 408).
Phthalate metaboliteb Free T4
c Total T3
c TSHd,e
MEP –0.011 (–0.048 to 0.026) 0.018 (–0.009 to 0.044) 0.94 (0.85 to 1.03)
MBP 0.003 (–0.023 to 0.028) –0.005 (–0.024 to 0.012) 1.02 (0.96 to 1.09)
MBzP –0.017 (–0.046 to 0.011) 0.001 (–0.018 to 0.021) 1.01 (0.94 to 1.08)
MEHP –0.013 (–0.042 to 0.017) –0.021 (–0.042 to –0.001)* 0.97 (0.90 to 1.04)
MEHHPf 0.008 (–0.017 to 0.033) –0.002 (–0.030 to 0.025) 0.98 (0.88 to 1.08)
MEOHPf 0.013 (–0.010 to 0.035) 0.003 (–0.024 to 0.028) 0.97 (0.88 to 1.06)
MEHP%f –0.030 (–0.055 to –0.005)* –0.016 (–0.044 to 0.014) 1.04 (0.94 to 1.15)
aAdjusted for age, BMI, current smoking, and time of day blood sample was collected. bNatural log-transformations of uri-
nary concentrations of phthalate metabolites were used in all models. cCoefﬁcient represents the change in hormone level
for an IQR change in phthalate metabolite concentration after back-transformation of the phthalate metabolite concentra-
tions; for an IQR change in phthalate metabolite concentration, a coefﬁcient equal to 0 indicates no change in hormone level,
a coefﬁcient < 0 indicates a decrease in hormone level, and a coefﬁcient > 0 indicates an increase in hormone level. dLog-
transformations of TSH concentration was used; free T4 and total T3 concentrations were modeled untransformed.
eCoefﬁcient represents a multiplicative change in hormone level for an IQR change in phthalate metabolite concentration
after back-transformation of both hormone and phthalate metabolite concentrations; for an IQR change in phthalate metabo-
lite concentration, a coefﬁcient equal to 1.0 indicates no change in hormone level, a coefﬁcient < 1.0 indicates a multiplica-
tive decrease in hormone level, and a coefﬁcient > 1.0 indicates a multiplicative increase in hormone level. fn = 208.
*p < 0.05.MEHP% and MEHP were included in the
models, the inverse association between
MEHP% and T4 remained (Table 5). When
MEHHP and MEHP were both included in
the models, T4 was inversely associated with
MEHP but positively associated with
MEHHP. There was no evidence of collinear-
ity between MEHP and MEHHP (i.e., the
SEs and 95% CIs were not inﬂated). Results
were identical when MEOHP was included
in the models instead of MEHHP (data not
shown), because MEHHP and MEOHP con-
centrations were highly correlated. Results for
T3 followed the same pattern as free T4 when
both MEHP and MEHHP were included in
the model, although associations were weaker
and not statistically signiﬁcant (Table 5). We
explored the interaction terms (MEHP ×
MEHHP or MEHP × MEHP%), but we
found no evidence of interaction when these
terms were added to the multivariate models.
To assess the robustness of the associations
and potential nonlinear relationships, we cate-
gorized SG-adjusted phthalate concentrations
into quintiles (n = 408). We found a suggestive
inverse trend for MEHP quintiles and T3
(p = 0.07), whereas we unexpectedly found a
signiﬁcant inverse trend for MEHP quintiles
and free T4 (p = 0.04). The regression coefﬁ-
cients for increasing quintiles of MEHP
appeared to plateau at quintile 4 (Figures 1
and 2). Among the subset of men with MEHP
oxidative metabolite measures (n = 208),
metabolite concentrations were categorized by
tertiles because of the smaller sample size. The
tertile analysis resulted in a suggestive inverse
trend between MEHP% and free T4 (p = 0.07;
Figure 3). When tertiles of both MEHP and
MEHHP were included, there was an inverse
association between free T4 and medium and
high tertiles of MEHP compared with the low-
est MEHP tertile (Figure 4). Similar to the
quintile analysis among all the men, the
relationships did not appear to be linear but
were suggestive of having a plateau. Results
were similar when MEHP and MEHP% were
included in the same model (Figure 5). In
addition, the suggestive association between
MEHP% and free T4 was no longer evident. 
We compared concentrations of (unad-
justed) urinary phthalate metabolites measured
in the present study with those among U.S.
males published in the Third National Report
on Human Exposure to Environmental
Chemicals (CDC 2005). Metabolite distribu-
tions were generally similar between the pre-
sent study and the national data, although we
found slightly lower concentrations of MEP,
MBP, and MBzP. Conversely, urinary concen-
trations of MEHP, MEHHP, and MEOHP
were somewhat higher in the present study
than those from the Third National Report.
For example, the median and 95th percentile
values for MEHP (unadjusted for SG) in the
present study were 6.3 and 112 ng/mL, respec-
tively, compared with 4.3 and 37.9 ng/mL in
the Third National Report (CDC 2005). 
Discussion
To our knowledge, this is the first study to
investigate the association between environ-
mental exposures to phthalates and serum
thyroid hormone and TSH levels in humans.
In the present study, we found evidence for an
inverse association between urinary MEHP
concentrations comparable with those
reported for the general U.S. population, and
free T4 and total T3 levels in adult men (CDC
2005). When metabolite concentrations were
modeled as continuous variables, there was an
inverse association between MEHP and T3.
We also found evidence of a plateau in the
inverse association for both T3 and free T4
with MEHP when exposure was categorized
by quintiles, suggesting that the relationship is
nonlinear; regression approaches that assume
linearity may not be appropriate for assessing
the relationship between MEHP and thyroid
hormones. Nonmonotonic inverse associa-
tions with a plateau or even a U shape may be
plausible, as has been demonstrated at low
doses for other hormonally active compounds
(Welshons et al. 2003).
The associations between MEHP and thy-
roid hormones in the present study are some-
what consistent with limited animal studies, in
which rats fed DEHP-contaminated diets had
histopathologic thyroid changes consistent
with hyperactivity and decreased T4 concen-
trations compared with controls, whereas T3
levels remained essentially unchanged (Hinton
et al. 1986; Howarth et al. 2001; Poon et al.
1997; Price et al. 1988). Conversely, rats
intravenously administered DEHP, at concen-
trations representing the amount that can
leach from polyvinyl chloride blood bags used
for human blood transfusions, showed
increased serum T3 and T4 levels (Gayathri
et al. 2004). This may suggest differences in
DEHP toxicokinetics by route of exposure
(ingestion vs. intravenous), although evidence
for this has not been shown in other studies to
date. In another study in rats fed a DEHP-
contaminated diet (2%) for 21 days, Bernal
et al. (2002) reported no difference in T4 lev-
els between exposed and control groups.
However, serum T4 levels were lower in
exposed rats (3.44 ± 0.53 ng/mL) than in con-
trols (4.20 ± 0.58 ng/mL); the lack of statisti-
cal signiﬁcance may have been due to a small
Meeker et al.
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Table 5. Adjusteda regression coefficients for a change in thyroid hormones associated with an IQR
increase in MEHP when also adjusted for MEHHP or MEHP% (n = 208).
Free T4 Total T3 TSHb
Estimate (95%CI) p-Value Estimate (95%CI) p-Value Estimate (95%CI) p-Value
MEHPb –0.046 (–0.088 to –0.004) 0.03 –0.027 (–0.074 to 0.021) 0.27 1.05 (0.89 to 1.25) 0.57
MEHHPb,c 0.043 (0.002 to 0.083) 0.04 0.017 (–0.028 to 0.065) 0.44 0.94 (0.80 to 1.11) 0.48
MEHPb 0.008 (–0.021 to 0.038) 0.59 –0.004 (–0.040 to 0.031) 0.80 0.97 (0.86 to 1.10) 0.66
MEHP%b,d –0.034 (–0.065 to –0.004) 0.02 –0.012 (–0.047 to 0.022) 0.46 1.05 (0.93 to 1.19) 0.41
aAdjusted for age, BMI, current smoking, and time of day blood sample was collected. bVariable was natural log-trans-
formed in the models. cCoefﬁcient represents change in thyroid hormone associated with IQR increase in MEHHP adjusted
for MEHP. dCoefﬁcient represents change in thyroid hormone associated with IQR increase in MEHP% adjusted for MEHP.
Figure 1. Regression coefficients (95% CIs) for a
change in total T3 associated with increasing quin-
tiles of SG-adjusted MEHP. Adjusted for age, BMI,
smoking, and time of day (n = 408).
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Figure 2. Regression coefficients (95% CIs) for a
change in free T4 associated with increasing quin-
tiles of SG-adjusted MEHP. Adjusted for age, BMI,
smoking, and time of day (n = 408).
0.20
0.10
0
–0.10
–0.20
Q1 Q2 Q3 Q4 Q5
C
o
e
f
f
i
c
i
e
n
t
 
(
9
5
%
 
C
I
)
 
f
o
r
 
c
h
a
n
g
e
i
n
 
f
r
e
e
 
T
4
 
(
n
g
/
d
L
)
MEHP concentration
Figure 3. Regression coefficients (95% CIs) for a
change in free T4 associated with increasing tertiles
of MEHP%. Adjusted for age, BMI, smoking, and
time of day (n = 208).
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number of animals in each group (n =1 2
and 7, respectively).
Virtually every tissue in the body is affected
by the thyroid hormones (Vander et al. 1998),
but studies on adverse health effects associated
with small deﬁcits of T4 or T3 in humans are
currently lacking (Boelart and Franklyn 2005;
Surks et al. 2004). There are a number of
potential mechanisms by which environmental
chemicals can affect thyroid function and dis-
rupt thyroid hormone homeostasis—including
involvement of the sodium–iodide symporter,
thyroid peroxidase enzyme, receptors for thy-
roid hormones or TSH, and transport proteins
or cellular uptake mechanisms—all of which
may interfere with the hypothalamic–
pituitary–thyroid axis at different levels (Boas
et al. 2006). Interaction between environmental
chemicals and iodothyronine deiodinases or
hepatic enzymes may also inﬂuence peripheral
metabolism of thyroid hormones (Qatanani
et al. 2005). Limited evidence exists that phtha-
lates may be involved in a number of these
mechanisms. Recent in vitro studies suggest
that phthalates induce changes in iodide uptake
of thyroid follicular cells by altering the tran-
scriptional activity of the sodium–iodide sym-
porter (Breous et al. 2005; Wenzel et al. 2005).
Ishihara et al. (2003) found that, in birds,
phthalates bind competitively to transthyretin,
a major thyroid hormone–binding transport
protein. In addition, Shimada and Yamauchi
(2004) found that phthalates (DBP and BBzP,
but not DEHP) inhibited [125I]T3 uptake in
tadpole red blood cells. Additional research is
needed for a better understanding of how
phthalates may inﬂuence the endocrine system
and thyroid function. Alternatively, at this time
we cannot rule out the possibility of reverse
causation whereby thyroid status may affect
DEHP and/or MEHP metabolism in a man-
ner that results in the observed inverse associa-
tions between DEHP metabolites and thyroid
hormones. A limitation of the present study
was that we did not measure levels of total T4
and free T3; these measurements, in conjunc-
tion with free T4 and total T3 levels, may have
provided additional mechanistic insights.
MEHP%, which provides information on
the proportion of DEHP excreted in the urine
as the monoester compared with the oxidative
metabolites but does not provide information
on the magnitude of DEHP exposure, was
inversely associated with free T4 (Table 4). In
addition, when both MEHP and oxidative
metabolites were considered in multivariate
models, we found an inverse association
between MEHP and free T4 along with evi-
dence of a positive association between
MEHHP and free T4 (Table 5, Figure 4).
These results suggest that the efﬁciency of an
individual’s ability to oxidize DEHP to
MEHHP and MEOHP may be related to
increased circulating free T4 levels. For
instance, for a given urinary concentration of
MEHP, an increased urinary concentration of
MEHHP or MEOHP was associated with
increased circulating free T4. Conversely, for a
given urinary concentration of MEHHP or
MEOHP, an increased MEHP concentration
is associated with decreased free T4. This phe-
nomenon was also reflected in the inverse
association between MEHP% and free T4,
where having an increased percentage of total
DEHP urinary metabolites excreted as MEHP
was associated with decreased T4 levels. This
suggests that for a given concentration of
MEHP, the higher the percentage of DEHP
excreted as MEHP (i.e., the more MEHP
there is relative to MEHHP and MEOHP in
the urine), the lower the serum T4. These
results may indicate that the pathways by
which DEHP is metabolized may impart vari-
able risks for altered thyroid hormones, based
on the proportion of DEHP that undergoes
oxidative metabolism compared with the pro-
portion that is excreted as the monoester. 
An understanding of the metabolism of
DEHP may provide insights into our observa-
tions on the relationships between DEHP
metabolites and thyroid hormone levels.
DEHP hydrolyzes ﬁrst to MEHP, which sub-
sequently metabolizes to MEHHP and
MEOHP, among other oxidative metabolites
(Koch et al. 2005; Silva et al. 2006a, 2006b).
These DEHP oxidative metabolites are 
more easily excreted in urine than MEHP.
Therefore, oxidation of MEHP could effec-
tively decrease internal body burden of
MEHP, which in turn, may have a protective
effect if MEHP is the bioactive metabolite.
DEHP interindividual variability in the per-
centage of MEHP and of oxidative metabolites
that are excreted in the urine has been observed
in the present study (Table 2) and elsewhere
(Becker et al. 2004; CDC 2005; Hauser et al.
2006; Silva et al. 2006a). Therefore, because
the proportion of urinary excretion of DEHP
as MEHP varies across individuals, urinary
concentrations of MEHP alone do not repre-
sent total body burden of DEHP exposure.
The inclusion of oxidative metabolites such as
MEHHP and MEOHP, as shown by our
results for free T4, may provide additional
insights into DEHP exposure and metabolism.
An alternative explanation is that the rela-
tive percentage of DEHP oxidative metabo-
lites in urine may represent a surrogate for the
function of phase 1 enzymes. If other hor-
monally active chemicals requiring phase 1
enzymes for detoxiﬁcation are associated with
thyroid function or thyroid hormone levels,
men with high MEHP%, which represents
low functionality of the phase 1 enzymes,
may also be “poor” metabolizers of the other
hormonally active chemicals. Presently, there
is no evidence to support this, although it
remains a possible alternative explanation. 
To our knowledge, other studies have not
explored the associations of thyroid hormone
levels with urinary phthalate monoester
metabolites or with oxidative metabolites of
DEHP. Further investigation is warranted on
the association between MEHP and thyroid
hormones, and the potential utility of
MEHP% as a phenotypic marker of the pro-
portion of DEHP excreted as MEHP and its
oxidative metabolites. As with other phtha-
lates, interindividual variability in DEHP
metabolism and urinary excretion of metabo-
lites exists (Becker et al. 2004; CDC 2005;
Hauser et al. 2006; Silva et al. 2006a).
Furthermore, the timing of collection of the
urine sample may partially account for differ-
ences in urinary concentrations of MEHP
and the oxidative metabolites among individ-
uals because the oxidative metabolites have a
longer half-life than MEHP (Koch et al.
2005). For instance, a urine sample collected
a few hours after DEHP exposure would con-
tain primarily MEHP. By contrast, a urine
sample collected 12 hr after DEHP exposure
may have higher concentrations of MEHHP
and MEOHP than of MEHP. The differ-
ences in half-lives of DEHP metabolites
should be taken into account when interpret-
ing the meaning of MEHP% following a sin-
gle pulsed exposure to DEHP. However, the
interpretation of MEHP% would be more
straightforward if the differences in half-lives
Figure 4. Regression coefficients (95% CIs) for a
change in free T4 associated with increasing ter-
tiles of MEHP and MEHHP. Adjusted for age, BMI,
smoking, and time of day (n = 208).
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Figure 5. Regression coefficients (95% CIs) for a
change in free T4 associated with increasing ter-
tiles of MEHP and MEHP%. Adjusted for age, BMI,
smoking, and time of day (n = 208).
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T1 T2 T3were not as inﬂuential on urinary concentra-
tions, as in the case of chronic exposure to
DEHP. 
Conclusion 
In the present study we found that urinary
MEHP concentrations comparable with those
found among the general U.S. population
(CDC 2005) may be associated with altered
free T4 and/or T3 levels in adult men.
However, this is the ﬁrst report of these asso-
ciations in humans; thus, additional research
is necessary to substantiate the observed ﬁnd-
ings. Future studies must also consider oxida-
tive DEHP metabolites relative to MEHP as a
potential marker of metabolic susceptibility to
DEHP exposure.
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